STAUB W RICHARD sold $1.3M of IQV

STAUB W RICHARD (See Remarks) sold 5,500 shares of IQVIA HOLDINGS INC. (IQV) at $232.68 ($1.28M total) on 2026-08-03.

Original reporting
SEC EDGAR · STAUB W RICHARD
Published Aug 4, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IQV
Neutral
medium confidence
Mentioned
$IQV
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

The only new fact is the reported open-market sale size, price, and post-transaction holdings; it does not include any company-specific operational or financial update.

02

Market read

Traders may note the insider sale for sentiment, but there is no fundamental catalyst in the filing.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs, and the filing does not indicate any change in IQVIA’s outlook.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-04 after-hours; sale executed 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for IQVIA Holdings Inc.

Company-level read

Ticker impact

$IQVNeutralMedium confidence
Context

IQVIA Form 4 shows officer Richard Staub sold 5,500 shares at $232.68 on 2026-08-03 for about $1.28M.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and typically fades.

Evidence & confidence

The filing is a primary-source Form 4, but it provides no earnings, guidance, deal, or regulatory catalyst. Insider sales are common and often not predictive without additional context.

Market effects

No clear sector read-through from a single insider sale at IQVIA.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could be interpreted by some traders as less routine, potentially adding short-term skepticism.

Key entities

  • IQVIA Holdings Inc.

    Subject of the Form 4 insider transaction disclosure.

  • STAUB W RICHARD

    Officer who sold 5,500 shares of IQVIA on 2026-08-03.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVHighAI 8/10

5 revealing analyst questions from IQVIA’s Q3 earnings call

IQVIA reported Q3 revenue of $4.43 billion, beating estimates by 1.5%, with adjusted EPS of $3.34, a 2% beat. The company raised full-year revenue guidance to $17.43 billion. Analysts discussed AI-driven workflows, margin improvements, and clinical bookings during the earnings call. CEO Ari Bousbib highlighted proprietary data and life sciences expertise as key differentiators.

$IQVMedAI 8/10

IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised

IQVIA Holdings Inc. reported Q3 2026 earnings with record bookings and raised guidance. Revenue was $4.428B, up 8% YoY, and adjusted EBITDA rose 8.7%. Challenges include FX headwinds and R&D backlog adjustments. Management highlighted AI adoption and strong biotech demand. Full-year 2026 guidance was increased, with revenue expected between $17.35B-$17.5B. No 2027 guidance was provided.

$IQVHighAI 8/10

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA reported Q3 revenue growth of 6.9% to $1.79B, with organic growth at 4%. AI adoption contributed to commercial and clinical momentum, with 415 AI agents deployed. The company raised its 2026 outlook, expecting revenue of $17.35B-$17.50B and adjusted EPS of $12.90-$13.00. Cash flow from operations was $825M, with free cash flow at $667M.

$IQVHighAI 9/10

IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.